- In April 2025, Morepen Laboratories, a leading active pharmaceutical ingredient (API) manufacturer, received approval from the Center for Drug Evaluation under China’s National Medical Products Administration (NMPA) for its anti-allergy API, Loratadine. This regulatory milestone is expected to enable Morepen to gain a substantial foothold in the Chinese market and further strengthen its position as a major global supplier of Loratadine
- In April 2025, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 and older who continue to experience symptoms despite treatment with H1 antihistamines.
- In October 2024, Alembic Pharmaceuticals announced that it had received final approval from the U.S. Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Alcaftadine Ophthalmic Solution. The approved product is deemed therapeutically equivalent to the reference listed drug (RLD), Lastacaft Solution, developed by AbbVie Inc
